XRA 5 Corp. /
Mural Oncology plc
XOMA Royalty subsidiary completes acquisition of Mural Oncology plc
Source for the buyer and target: XOMA Royalty Corp
For the buyer and target.
“Transaction Agreement, by and among XOMA Royalty Corporation, XRA 5 Corp. and Mural Oncology plc, dated August 20, 2025.”
Published 5 Dec 2025
Open the sourceWhat happened
XRA 5 Corp., a wholly-owned subsidiary of XOMA Royalty Corporation, completed its acquisition of Mural Oncology plc on Dec. 5, 2025, through a court-sanctioned scheme of arrangement. [01]
Mural shareholders were entitled to receive $2.035 per share in cash. [01]
The source
Everything on this page comes from the source below, quoted word for word.
XOMA Royalty subsidiary completes acquisition of Mural Oncology plc
This document is the source for the companies, stage, figure and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
Closed
“XOMA Royalty subsidiary completes acquisition of Mural Oncology plc XRA 5 Corp., a wholly-owned subsidiary of XOMA Royalty Corporation, completed its acquisition of Mural Oncology plc on Dec. 5, 2025, through a court-…”
Open the source
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Get ProAlready a member? Sign in
Pro is open to everyone.
By email · Weekly